Major Clinical Trial in Sub-Saharan Africa (ANTICOV) to Study Hydroxychloroquine & Other Repurposed Treatments Targeting Early Onset COVID-19

Major Clinical Trial in Sub-Saharan Africa (ANTICOV) to Study Hydroxychloroquine & Other Repurposed Treatments Targeting Early Onset COVID-19

An international network of research institutions and thirteen African nations have formed an alliance to conduct the largest COVID-19 clinical trial of its kind in Africa with an emphasis on investigating treatment options for mild and moderate cases at onset of infection as well as prevent increases in hospitalization that could stretch already challenged African health delivery systems. Now the ANTICOV consortium, consisting of 19 trial site organizations in 13 countries includes 26 recognized global research and development (R&D) organizations, led by the Drug for Neglected Diseases initiative (DNDi), spearheads the ANTICOV study. With an emphasis on existing repurposed therapies, only two actual drugs are named as of this writing, including Hydroxychloroquine. Interestingly, the study will occur only in Sub-Saharan populations precluding all other parts of the African continent. While the developed world focuses on vaccines and advanced novel therapies (and argues about hydroxychloroquine), a new and important study focuses in on this antimalarial drug as well as other candidates, including those targeting hepatitis C and parasite infections. With the involvement of Wellc...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee